Yafang Deng
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Yafang Deng has a total of 30 co-authors. Here are the top co-authors by number of shared publications:
- Haitao Li
Tsinghua University
2 shared publications - Bo Peng
MOE Key Laboratory of Protein Sciences, State Key Laboratory of Molecular Oncology, Beijing Frontier Research Center for Biological Structure, School of Medicine, Tsinghua University, Beijing 100084, China
1 shared publication - Chen Yu
Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital (PUMCH), Chinese Academy of Medical Sciences and Peking Union Medical College; National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC‐DID), Ministry of Science and Technology; State Key Laboratory of Complex Severe and Rare Diseases; Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education Beijing China
1 shared publication - Daliang Wang
State Key Laboratory of Molecular Oncology, MOE Key Laboratory of Protein Sciences, Beijing Frontier Research Center for Biological Structure, School of Basic Medical Sciences, Tsinghua University , Beijing 100084
1 shared publication Fan Feng
MOE Key Laboratory of Protein Sciences, State Key Laboratory of Molecular Oncology, Beijing Frontier Research Center for Biological Structure, School of Medicine, Tsinghua University, Beijing 100084, China
1 shared publication- Fan Zhao
MOE Key Laboratory of Protein Sciences, State Key Laboratory of Molecular Oncology, Beijing Frontier Research Center for Biological Structure, School of Medicine, Tsinghua University, Beijing 100084, China
1 shared publication
Latest Publications
- Open Access
- 11 September 2025
- Published by Wiley in Pediatric Investigation
- Vol. 9 (4) , 325-336
Global, regional, and national burden of brain and central nervous system cancer in children and adolescents, 1990–2021: A systematic analysis of the Global Burden of Disease study 2021
Importance: Brain and central nervous system (CNS) cancers are the most common pediatric solid tumors, significantly affecting the patients’ life expectancy and quality. Objective: To examine the disease burden of brain and CNS cancer in children and adolescents from 1990 to 2021 across various age groups, sexes, and socio‐demographic index levels, at the global, regional, and national levels. Methods: Data, including the incidence, mortality, and disability‐adjusted life years (DALYs) of brain and CNS cancer in children and adolescents, were obtained from the 2021 Global Burden of Diseases, Injuries, and Risk Factors Study. Temporal trends were evaluated using the Joinpoint regression model. The relationship between disease burden and socioeconomic development, as well as health inequality, was examined. Results: In 2021, the global age‐standardized incidence rate of brain and CNS cancers among patients aged 0–20 years was 1.55 per 100 000 population. From 1990 to 2021, the global age‐standardized mortality rate (ASMR) declined from 1.14 to 0.76 per 100 000, and the age‐standardized DALY rate (ASDR) decreased from 94.29 to 62.79 per 100 000. Over the past three decades, most regions and countries and territories have shown declining trends in ASMR and ASDR. Global inequality of disease burden persists, with regions possessing higher socioeconomic statuses exhibiting lower ASMR, ASDR, and mortality‐to‐incidence ratio. Interpretation: The decline in ASMR and ASDR of pediatric brain and CNS cancer indicates improvements in disease management and patient outcomes. Enhancing diagnostic and therapeutic strategies, improving life quality, and promoting health equity are crucial directions for future research.
- 11 September 2025
- Published by Wiley in Pediatric Investigation
- Vol. 9 (4) , 325-336
Open AccessGlobal, regional, and national burden of brain and central nervous system cancer in children and adolescents, 1990–2021: A systematic analysis of the Global Burden of Disease study 2021
Importance: Brain and central nervous system (CNS) cancers are the most common pediatric solid tumors, significantly affecting the patients’ life expectancy and quality. Objective: To examine the disease burden of brain and CNS cancer in children and adolescents from 1990 to 2021 across various age groups, sexes, and socio‐demographic index levels, at the global, regional, and national levels. Methods: Data, including the incidence, mortality, and disability‐adjusted life years (DALYs) of brain and CNS cancer in children and adolescents, were obtained from the 2021 Global Burden of Diseases, Injuries, and Risk Factors Study. Temporal trends were evaluated using the Joinpoint regression model. The relationship between disease burden and socioeconomic development, as well as health inequality, was examined. Results: In 2021, the global age‐standardized incidence rate of brain and CNS cancers among patients aged 0–20 years was 1.55 per 100 000 population. From 1990 to 2021, the global age‐standardized mortality rate (ASMR) declined from 1.14 to 0.76 per 100 000, and the age‐standardized DALY rate (ASDR) decreased from 94.29 to 62.79 per 100 000. Over the past three decades, most regions and countries and territories have shown declining trends in ASMR and ASDR. Global inequality of disease burden persists, with regions possessing higher socioeconomic statuses exhibiting lower ASMR, ASDR, and mortality‐to‐incidence ratio. Interpretation: The decline in ASMR and ASDR of pediatric brain and CNS cancer indicates improvements in disease management and patient outcomes. Enhancing diagnostic and therapeutic strategies, improving life quality, and promoting health equity are crucial directions for future research.
- Open Access
- 7 March 2025
- Published by Oxford University Press (OUP) in Protein & Cell
Unfolding HBx for an epigenetic switch of HBV cccDNA minichromosome
- 7 March 2025
- Published by Oxford University Press (OUP) in Protein & Cell
Open AccessUnfolding HBx for an epigenetic switch of HBV cccDNA minichromosome
- 17 January 2025
- Published by Wiley in International Journal of Rheumatic Diseases
- Vol. 28 (1) , e70066
Chinese Registry of Rheumatoid Arthritis (CREDIT) VI: Temporal Trends in Patients With Early Rheumatoid Arthritis and Moderate‐To‐Severe Disease Activity ‐ A Multicenter Cohort Study of Treatment Strategies and Outcomes
Aim: The continuous update of international guidelines and enhanced availability of biological disease‐modifying antirheumatic drugs (bDMARDs) and targeted synthetic DMARDs (tsDMARDs) have made a significant impact on the diagnosis and treatment of early rheumatoid arthritis (ERA). This study aims to systematically evaluate the current treatment strategies and outcomes within a large‐scale cohort of patients with ERA. Methods: Data from the Chinese Registry of Rheumatoid Arthritis (CREDIT), a large multicenter Chinese registry of RA, were collected to analyze temporal trends in clinical profiles, therapeutic strategies, and treatment outcomes among patients with ERA. Results: From November 2016 to October 2023, A total of 2722 patients with follow‐up information for 6 months were included. The use of methotrexate (MTX) increased annually and has become the predominant DMARD as the initial treatment. Following initial therapy, 1059 (38.9%) patients achieved the therapeutic target of low disease activity and remission. Age ≥ 50 years (adjusted OR 0.70 [95% CI 0.59–0.83]; p < 0.001), high baseline disease activity (adjusted OR 0.48 [95% CI 0.41–0.57]; p < 0.001), csDMARD monotherapy other than MTX (adjusted OR 0.55 [95% CI 0.41–0.73]; p < 0.001), and the use of b/tsDMARDs without a csDMARD combination (adjusted OR 0.57 [95% CI 0.36–0.87]; p = 0.011) were associated with lower target attainment rates. For patients who did not achieve the treatment target after initial therapy, the use of b/tsDMARDs increased after 2020, although the extent of therapeutic escalation remained suboptimal. Conclusion: Treatment of patients with ERA in China has become more standardized. Adherence to guideline‐directed therapeutic regimens has emerged as a significant determinant of therapeutic target achievement. The increased prevalence of b/tsDMARDs would benefit more patients in ameliorating the disease.
- 17 January 2025
- Published by Wiley in International Journal of Rheumatic Diseases
- Vol. 28 (1) , e70066
Chinese Registry of Rheumatoid Arthritis (CREDIT) VI: Temporal Trends in Patients With Early Rheumatoid Arthritis and Moderate‐To‐Severe Disease Activity ‐ A Multicenter Cohort Study of Treatment Strategies and Outcomes
Aim: The continuous update of international guidelines and enhanced availability of biological disease‐modifying antirheumatic drugs (bDMARDs) and targeted synthetic DMARDs (tsDMARDs) have made a significant impact on the diagnosis and treatment of early rheumatoid arthritis (ERA). This study aims to systematically evaluate the current treatment strategies and outcomes within a large‐scale cohort of patients with ERA. Methods: Data from the Chinese Registry of Rheumatoid Arthritis (CREDIT), a large multicenter Chinese registry of RA, were collected to analyze temporal trends in clinical profiles, therapeutic strategies, and treatment outcomes among patients with ERA. Results: From November 2016 to October 2023, A total of 2722 patients with follow‐up information for 6 months were included. The use of methotrexate (MTX) increased annually and has become the predominant DMARD as the initial treatment. Following initial therapy, 1059 (38.9%) patients achieved the therapeutic target of low disease activity and remission. Age ≥ 50 years (adjusted OR 0.70 [95% CI 0.59–0.83]; p < 0.001), high baseline disease activity (adjusted OR 0.48 [95% CI 0.41–0.57]; p < 0.001), csDMARD monotherapy other than MTX (adjusted OR 0.55 [95% CI 0.41–0.73]; p < 0.001), and the use of b/tsDMARDs without a csDMARD combination (adjusted OR 0.57 [95% CI 0.36–0.87]; p = 0.011) were associated with lower target attainment rates. For patients who did not achieve the treatment target after initial therapy, the use of b/tsDMARDs increased after 2020, although the extent of therapeutic escalation remained suboptimal. Conclusion: Treatment of patients with ERA in China has become more standardized. Adherence to guideline‐directed therapeutic regimens has emerged as a significant determinant of therapeutic target achievement. The increased prevalence of b/tsDMARDs would benefit more patients in ameliorating the disease.
- 15 November 2023
- Published by Elsevier in Journal of Molecular Biology
- Vol. 436 (7) , 168371
Molecular Basis for SPINDOC-Spindlin1 Engagement and Its Role in Transcriptional Attenuation
- 15 November 2023
- Published by Elsevier in Journal of Molecular Biology
- Vol. 436 (7) , 168371
Molecular Basis for SPINDOC-Spindlin1 Engagement and Its Role in Transcriptional Attenuation